- Home
- BIIB vs LI Comparison
BIIB vs LI Comparison
Compare BIIB & LI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- LI
- Stock Information
- Founded
- BIIB 1978
- LI 2015
- Country
- BIIB United States
- LI China
- Employees
- BIIB N/A
- LI N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- LI Auto Manufacturing
- Sector
- BIIB Health Care
- LI Consumer Discretionary
- Exchange
- BIIB Nasdaq
- LI Nasdaq
- Market Cap
- BIIB 25.1B
- LI 28.7B
- IPO Year
- BIIB 1991
- LI 2020
- Fundamental
- Price
- BIIB $149.02
- LI $24.44
- Analyst Decision
- BIIB Buy
- LI Buy
- Analyst Count
- BIIB 26
- LI 6
- Target Price
- BIIB $248.00
- LI $36.43
- AVG Volume (30 Days)
- BIIB 1.6M
- LI 5.3M
- Earning Date
- BIIB 02-11-2025
- LI 10-31-2024
- Dividend Yield
- BIIB N/A
- LI N/A
- EPS Growth
- BIIB 10.05
- LI 56.67
- EPS
- BIIB 11.06
- LI 1.37
- Revenue
- BIIB $9,607,500,000.00
- LI $20,232,143,532.00
- Revenue This Year
- BIIB N/A
- LI $19.64
- Revenue Next Year
- BIIB N/A
- LI $31.36
- P/E Ratio
- BIIB $13.47
- LI $17.89
- Revenue Growth
- BIIB N/A
- LI 42.25
- 52 Week Low
- BIIB $145.07
- LI $17.44
- 52 Week High
- BIIB $268.30
- LI $46.44
- Technical
- Relative Strength Index (RSI)
- BIIB 32.44
- LI 58.31
- Support Level
- BIIB $145.07
- LI $21.58
- Resistance Level
- BIIB $149.92
- LI $23.99
- Average True Range (ATR)
- BIIB 3.81
- LI 0.58
- MACD
- BIIB 0.05
- LI 0.28
- Stochastic Oscillator
- BIIB 22.51
- LI 78.14
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 376,000 NEVs in 2023, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.